JP5128578B2 - 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 - Google Patents

解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 Download PDF

Info

Publication number
JP5128578B2
JP5128578B2 JP2009503576A JP2009503576A JP5128578B2 JP 5128578 B2 JP5128578 B2 JP 5128578B2 JP 2009503576 A JP2009503576 A JP 2009503576A JP 2009503576 A JP2009503576 A JP 2009503576A JP 5128578 B2 JP5128578 B2 JP 5128578B2
Authority
JP
Japan
Prior art keywords
opioid receptor
alkyl
receptor antagonist
disorders
dissociative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009503576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532434A (ja
JP2009532434A5 (https=
Inventor
ラルス ヘルマン，ホルガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emodys GmbH
Original Assignee
Emodys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys GmbH filed Critical Emodys GmbH
Publication of JP2009532434A publication Critical patent/JP2009532434A/ja
Publication of JP2009532434A5 publication Critical patent/JP2009532434A5/ja
Application granted granted Critical
Publication of JP5128578B2 publication Critical patent/JP5128578B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2009503576A 2006-04-04 2007-04-03 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 Expired - Fee Related JP5128578B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006015733.8 2006-04-04
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
DE102006016991.3 2006-04-11
PCT/EP2007/053248 WO2007115975A2 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (3)

Publication Number Publication Date
JP2009532434A JP2009532434A (ja) 2009-09-10
JP2009532434A5 JP2009532434A5 (https=) 2010-11-11
JP5128578B2 true JP5128578B2 (ja) 2013-01-23

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503576A Expired - Fee Related JP5128578B2 (ja) 2006-04-04 2007-04-03 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用

Country Status (17)

Country Link
US (1) US8063059B2 (https=)
EP (1) EP2001456B1 (https=)
JP (1) JP5128578B2 (https=)
AT (1) ATE450256T1 (https=)
AU (1) AU2007236003B2 (https=)
CA (1) CA2646899C (https=)
CY (1) CY1109862T1 (https=)
DE (1) DE502007002185D1 (https=)
DK (1) DK2001456T3 (https=)
EA (1) EA014820B1 (https=)
ES (1) ES2337622T3 (https=)
HR (1) HRP20100113T1 (https=)
PL (1) PL2001456T3 (https=)
PT (1) PT2001456E (https=)
RS (1) RS51211B (https=)
SI (1) SI2001456T1 (https=)
WO (1) WO2007115975A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
ES2694352T3 (es) * 2013-12-20 2018-12-20 H. Lundbeck A/S Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
LT3137081T (lt) 2014-04-28 2018-02-26 Orphomed, Inc. Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
EP1365756A2 (en) * 2000-08-15 2003-12-03 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CA2521396A1 (en) * 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
JP2007526328A (ja) * 2004-03-02 2007-09-13 ファルマシア コーポレーション 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
CN103087133B (zh) * 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
EP1750675B1 (en) * 2004-06-02 2008-10-29 Galephar M/F Stable oral pharmaceutical compositions of buprenorphine and salt thereof

Also Published As

Publication number Publication date
US8063059B2 (en) 2011-11-22
ES2337622T3 (es) 2010-04-27
SI2001456T1 (sl) 2010-04-30
AU2007236003A1 (en) 2007-10-18
RS51211B (sr) 2010-12-31
HRP20100113T1 (hr) 2010-04-30
AU2007236003B2 (en) 2012-10-18
EA014820B1 (ru) 2011-02-28
EP2001456B1 (de) 2009-12-02
JP2009532434A (ja) 2009-09-10
DK2001456T3 (da) 2010-04-12
DE502007002185D1 (de) 2010-01-14
CA2646899A1 (en) 2007-10-18
US20090181999A1 (en) 2009-07-16
CY1109862T1 (el) 2014-09-10
WO2007115975A2 (de) 2007-10-18
ATE450256T1 (de) 2009-12-15
CA2646899C (en) 2014-05-06
PL2001456T3 (pl) 2010-05-31
WO2007115975A3 (de) 2008-02-14
EA200802104A1 (ru) 2009-04-28
PT2001456E (pt) 2010-03-03
EP2001456A2 (de) 2008-12-17

Similar Documents

Publication Publication Date Title
JP5128578B2 (ja) 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用
US10952976B2 (en) Compositions and methods for treating respiratory depression with fenfluramine
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
JP2005537268A (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
CN104853755B (zh) 包含沃替西汀和多奈哌齐的组合物
Li et al. The effect of small dose sufentanil on emergence agitation in preschool children following sevoflurane anesthesia for elective repair of unilateral inguinal hernia
CN109640998A (zh) 治疗昼夜节律性睡眠障碍的方法
JP7108041B2 (ja) 睡眠障害の治療及び予防
JP2012121890A (ja) 神経接続欠陥、例えば精神分裂病及び自閉症の治療においてエポチロン（ｅｐｏｔｈｉｌｏｎｅ）を使用する方法
JP4718771B2 (ja) 本態性振戦の予防・治療剤
CN101677998B (zh) 包含西洛他唑的治疗精神分裂症药物
TW200528098A (en) Treatment of insomnia in human patients
EP3130339B1 (en) A compound for use in the treatment of comorbid anxiety disorder and depression disorder
RU2820449C2 (ru) Анальгезирующие композиции
WO2023120551A1 (ja) 自閉スペクトラム症治療のためのオピオイドの使用
CN101111266A (zh) 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
CZ300781B6 (cs) Použití R-(+)-alfa-(2,3-dimethoxyfenyl)-1-[2-(4-fluorfenyl)ethyl]-4-piperidinmethanolu pro lécení poruch spánku
HK1212601B (en) Compositions comprising vortioxetine and donepezil

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121002

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121031

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151109

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees